• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by TenX Keane Acquisition (Amendment)

    2/8/23 8:39:48 AM ET
    $TENK
    Blank Checks
    Finance
    Get the next $TENK alert in real time by email
    SC 13G/A 1 lf_sc13gz.htm SCHEDULE 13G/A Schedule 13G

     

    OMB APPROVAL

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    OMB Number:3235-0145 

    Expires:Febuary 28, 2009 

    Estimated average burden
    hours per response ....10.4

     

     

    SCHEDULE 13G

    Under the Securities and Exchange Act of 1934

    (Amendment No.         1        )*

     

    TenX Keane Acquistion

    (Name of Issuer)

     

    Ordinary shares, par value $ 0.0001

    (Title of Class of Securities)

     

    G8708L104

    (CUSIP Number)

     

     

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    o  Rule 13d-1(b)

    ý  Rule 13d-1(c)

    o  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1


     

    CUSIP No.    G8708L104

    1.Names of Reporting Persons. 

    I.R.S. Identification Nos. of above persons (entities only). 

    Feis Equities LLC 

    2.Check the Appropriate Box if a Member of a Group 

    (a)o 

    (b)o 

    3.SEC Use Only 

    4.Citizenship or Place of OrganizationState of Illinois 

    Number of Shares Beneficially Owned by Each Reporting Person With

    5.Sole Voting Power542,006 

    6.Shared Voting Power0 

    7.Sole Dispositive Power542,006 

    8.Shared Dispositive Power0 

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 

    542,006 

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)      o 

    11.Percent of Class Represented by Amount in Row (9) 

    6.06% 

    12.Type of Reporting Person (See Instructions) 

    OO-Limited Liability Company 


    2


     

    CUSIP No.    G8708L104

    1.Names of Reporting Persons. 

    I.R.S. Identification Nos. of above persons (entities only). 

    Lawrence M. Feis 

    2.Check the Appropriate Box if a Member of a Group 

    (a)o 

    (b)o 

    3.SEC Use Only 

    4.Citizenship or Place of OrganizationU.S.A. 

    Number of Shares Beneficially Owned by Each Reporting Person With

    5.Sole Voting Power542,006 

    6.Shared Voting Power0 

    7.Sole Dispositive Power542,006 

    8.Shared Dispositive Power0 

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 

    542,006 

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)      o 

    11.Percent of Class Represented by Amount in Row (9)  

    6.06% 

    12.Type of Reporting Person (See Instructions) 

    IN 


    3


     

    Item 1.

    The name and address of the principal executive offices of the Issuer are:

    TenX Keane Acquistion

    420 Lexington Ave, Suite 2446

    New York, NY  10170

    Item 2.

    This statement on Schedule 13G is being filed by:

    (a) Name of Person Filing 

     

    (i)Feis Equities LLC 

    (ii)Lawrence M. Feis 

     

     

     

     

     

    (b)Address: 

    The address of the business office of each of the Reporting Persons is:

     

    20 North Wacker Drive

    Suite 2115

    Chicago, Illinois  60606

     

     

     

     

     

    (c)Citizenship/Place: 

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated hereto by reference for each Reporting Person.

     

    (d)Title of Class of Securities: 

    Ordinary shares, par value $ 0.0001 (the “Shares”)

     

    (e)CUSIP Number: 

     

    G8708L104

     

     

     


    4


    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a)oBroker or dealer registered under section 15 of the Act (15 U.S.C. 78o). 

    (b)oBank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). 

    (c)oInsurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). 

    (d)oInvestment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). 

    (e)oAn investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); 

    (f)oAn employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); 

    (g)oA parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); 

    (h)oA savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); 

    (i)oA church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); 

    (j)oGroup, in accordance with §240.13d-1(b)(1)(ii)(J). 

    Item 4.  Ownership

     

    The information required by Items 4(a)-(c) is set forth in Rows 5-11 of the cover page for each Reporting Person and incorporated by reference herein.

     

    The percentage set forth in row 11 of the cover page for each Reporting Person is based on 8,941,000 Ordinary shares outstanding as of November 28,2022, as reported by the Issuer in its quarterly 10-Q filing for the period ending September 30, 2022, filed with the Securities and Exchange Commission on November 28, 2022.


    5


     

    Item 5.  Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  o

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.

    Item 8.  Identification and Classification of Members of the Group

    Not applicable.

    Item 9.  Notice of Dissolution of Group

    Not applicable.

    Item 10.  Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    6


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:February 6, 2023 

     

     

     

     

    Date:February 6, 2023 

     

    FEIS EQUITIES LLC

    By:/s/ Lawrence M. Feis 

                Managing Member LLC

     

     

    LAWRENCE M. FEIS

    By:/s/ Lawrence M. Feis 

     


    7


     

     

    EXHIBIT INDEX

     

    Ex.

     

    Page No.

     

     

     

    A

    Joint Filing Agreement

    9


    8


     

    JOINT FILING AGREEMENT

     

    The undersigned hereby agree that the statement on Schedule 13G with respect to the Ordinary shares of TenX Keane Acquistion dated as of February 6, 2023 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

     

    FEIS EQUITIES LLC 

    By:/s/ Lawrence M. Feis 

    Managing Member LLC 

     

     

    LAWRENCE M. FEIS 

    By:/s/ Lawrence M. Feis 

     

    Date:  February 6, 2023


    9

    Get the next $TENK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TENK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TENK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update

      TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. (CTOR) New York, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- On August 7, 2024, TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) ("TenX"), a publicly traded special purpose acquisition company, was notified by The Nasdaq Stock Market that trading in TenX's securities had been halted for "additional information requested" from the company. The trading halt was imposed following volatility in the trading price and volume of TenX's securities on Wednesday, August 7, 202

      8/9/24 7:30:00 AM ET
      $CTXR
      $TENK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Blank Checks
      Finance
    • TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals

      TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets New York, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) (the "TenX"), a publicly traded special purpose acquisition company, today announced that on August 2, 2024, at the extraordinary general meeting, its shareholders voted to approve the previously announced business combination with the wholly own

      8/5/24 8:00:00 AM ET
      $CTXR
      $TENK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Blank Checks
      Finance
    • Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

      Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc. Citius Pharmaceuticals to retain approximately 90% majority control post transaction    Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets CRANFORD, N.J., Aug. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that shareholders of TenX Keane

      8/5/24 8:00:00 AM ET
      $CTXR
      $TENK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Blank Checks
      Finance

    $TENK
    SEC Filings

    See more
    • SEC Form 25-NSE filed by TenX Keane Acquisition

      25-NSE - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      8/13/24 4:33:39 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form 10-Q filed by TenX Keane Acquisition

      10-Q - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

      8/9/24 4:22:23 PM ET
      $TENK
      Blank Checks
      Finance
    • TenX Keane Acquisition filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - TenX Keane Acquisition (0001851484) (Filer)

      8/2/24 8:45:17 PM ET
      $TENK
      Blank Checks
      Finance

    $TENK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Dutia Suren G

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      8/14/24 6:29:05 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form 4 filed by Director Holubiak Myron Z

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      8/14/24 6:28:37 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form 4 filed by Chief Medical Officer Czuczman Myron

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      8/14/24 6:28:05 PM ET
      $TENK
      Blank Checks
      Finance

    $TENK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by TenX Keane Acquisition

      SC 13D/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      8/15/24 12:53:48 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by TenX Keane Acquisition (Amendment)

      SC 13G/A - TenX Keane Acquisition (0001851484) (Subject)

      3/7/24 4:06:26 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form SC 13G filed by TenX Keane Acquisition

      SC 13G - TenX Keane Acquisition (0001851484) (Subject)

      2/13/24 8:09:57 PM ET
      $TENK
      Blank Checks
      Finance